Clinical trials
Breast Cancer Risk clinical trials
Below are recruiting breast cancer risk clinical trials, each written for real people, not researchers. We’re tracking 741 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06949410RecruitingPhase 1
HER2 vaccine study for high-risk breast cancer
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Indianapolis, IndianaAges 18 years+ - NCT06954831RecruitingPhase 2
Short-course radiation for early-stage breast cancer
This trial tests a shorter, more intense radiation schedule for people with stage I-III breast cancer after lumpectomy. It aims to find if giving a higher daily dose over fewer sessions is safe and effective.
Arcadia, CaliforniaAges 40 years+ - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06959537RecruitingPhase 1
Combination drug therapy for triple negative breast cancer
This trial tests a new combination of three drugs (cyclophosphamide, axatilimab, and retifanlimab) for people with metastatic triple negative breast cancer. The goal is to see if adding a low dose of chemotherapy can make the immunotherapy work better.
Houston, TexasAges 18 years+ - NCT06961955RecruitingPhase 2
Shorter versus longer whole breast radiation for early-stage breast cancer
This trial compares a 5-day course of whole breast radiation plus a boost to the standard 9-day course for people with early-stage breast cancer who have certain risk factors, such as high-grade tumors or younger age. The goal is to see if the shorter treatment is just as safe and effective.
Salt Lake City, UtahAges 18 years+ - NCT06962670Recruiting
Cancer risk study using digital and molecular markers
This study uses a smartphone app and biological markers to predict cancer risk. It is testing whether digital and molecular data can help identify cancer earlier, especially in women with a history of certain cancers.
Please Refer to Project Homepage For Details (see Link Below), BavariaAges 18 years+ - NCT06967103RecruitingPhase 2
New drug before breast cancer surgery
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
ZhengzhouAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT07019363RecruitingPhase 3
CDK4/6 inhibitor plus hormone therapy for high-risk breast cancer
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
ShanghaiAges 18–70 - NCT07021846Recruiting
Higher-dose radiation for early breast cancer in young women
This study tests a higher-dose, faster radiation treatment for young women with early breast cancer who have certain risk factors. The goal is to reduce the chance of cancer coming back while keeping side effects low.
RomaAges 18–50 - NCT07039552Recruiting
Ovarian cancer risk check for family members
This study looks at family members of people with ovarian cancer to build a better tool for predicting their risk. If you have a BRCA1 or BRCA2 gene mutation, you may be able to join.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07057427RecruitingPhase 3
Nab-paclitaxel vs TCbHP for HER2-positive early breast cancer
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Zhengzhou, HenanAges 18–70 - NCT07070128Recruiting
AI screening tool for breast cancer genetic risk
This trial tests an AI tool that predicts genetic risk for breast cancer. It may help women identified as high-risk by their breast surgeon get quicker genetic counseling.
Golania, GoiásAges Any age - NCT07076147Recruiting
Breast cancer screening follow-up for moderate-risk women
This study looks at how well women with a moderate risk of breast cancer follow their screening recommendations (like yearly MRI or mammogram). It may help women who have certain genetic variants or a higher calculated risk stay on top of their breast health.
Los Angeles, CaliforniaAges 30–75 - NCT07076485RecruitingPhase 2
Shorter radiation after surgery for node-positive breast cancer
This trial tests shorter radiation schedules for people with breast cancer that has spread to lymph nodes or is high-risk. It aims to find a shorter course of radiation that is just as effective after surgery.
Loveland, ColoradoAges 18 years+ - NCT07084571Recruiting
Testing Tissue Sampling Over Time in Advanced Breast Cancer
This study is testing whether it is safe and practical to take multiple small tissue samples (biopsies) from different sites of your breast cancer over time. The goal is to learn how breast cancer changes as it grows, which could help doctors develop better treatments.
LondonAges 18 years+ - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07137468Recruiting
Everyday exposures and breast cancer risk study
This study looks at how everyday things like chemicals and body weight might affect breast cancer risk. It is for people in the Acres Home community who have had breast cancer or who have a family member who has had it.
Houston, TexasAges 18 years+ - NCT07142096Recruiting
MitoQ before surgery for triple-negative breast cancer
This trial tests whether taking the supplement MitoQ before standard surgery can help treat triple-negative breast cancer. You would take MitoQ for a short time between diagnosis and surgery to see if it slows tumor growth.
BrusselsAges 18 years+ - NCT07151911Recruiting
Study of drugs for high-risk early breast cancer
This study looks at the effectiveness of the drugs abemaciclib and olaparib plus hormone therapy for people with high-risk, hormone receptor-positive, HER2-negative early breast cancer. It aims to understand how well these treatments work in real-world settings.
Modena, ModenaAges 18 years+ - NCT07159451RecruitingPhase 2
Elacestrant for premenopausal women with early breast cancer
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
VillejuifAges 18 years+ - NCT07179744Recruiting
Skipping radiation for low-risk node-positive breast cancer
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
Guangzhou, GuangdongAges 18–70 - NCT07193394RecruitingPhase 2
Tucatinib and trastuzumab for HER3-mutant breast cancer
This trial tests a combination of two targeted drugs (tucatinib and trastuzumab) for people with a specific gene change (HER3 mutation) in advanced breast cancer that has spread or cannot be removed by surgery. It may be an option if you have already had at least two previous treatments.
BordeauxAges 18 years+
Hear when a new Breast Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer risk?
- Yes. Clin2 currently lists 741 recruiting breast cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.